PET Scan Insurance Denied: How to Fight Back

A PET scan can be the most important diagnostic test in a cancer patient's care — revealing whether cancer has spread, whether treatment is working, and whether surgery is necessary. Yet PET scans are among the most frequently denied imaging tests, primarily because of strict Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization rules, Medicare coverage limitations, and insurer criteria that don't always align with clinical practice. Here is how to fight a PET scan denial.

Why PET Scans Are Denied

Prior authorization denied. Almost every commercial insurer, Medicare Advantage plan, and Medicaid managed care plan requires prior authorization for PET scans. Because PET is expensive (typically $3,000–$6,000 per scan), insurers scrutinize authorizations carefully. Denial at the authorization stage is the most common barrier.

Indication not covered under insurer criteria. Insurers often maintain lists of approved PET scan indications. Coverage is strong for specific cancers (lung, colorectal, lymphoma, melanoma, esophageal, cervical, ovarian, head and neck, thyroid) but may be denied for other cancers or non-oncology indications (e.g., cardiac PET or PET for neurological conditions) unless clinical criteria are met.

Medicare NCD (National Coverage Determination) limitations. Traditional Medicare covers PET scans under specific NCDs. For oncology, Medicare covers PET for:

• Initial staging of most solid tumors and lymphomas
• Subsequent treatment strategy (i.e., is the cancer responding to treatment?)
• Diagnosis of suspected recurrence

However, Medicare does not cover PET for prostate cancer staging under certain circumstances, and coverage for rare cancers may require supporting documentation. If Medicare denies a PET claim based on NCD, the appeal goes through the Medicare appeal process.

Frequency limits. Insurers may approve one PET scan for initial staging but deny subsequent scans for treatment monitoring, citing frequency limits or inadequate documentation of clinical change.

Non-oncology PET indications. PET is increasingly used for cardiac viability assessment, neurological conditions (including Alzheimer's disease diagnosis), and infection/inflammation. Many commercial plans do not cover PET for neurological indications unless strict criteria are met. Medicare covers amyloid PET (for Alzheimer's) under a Coverage with Evidence Development framework, but only in specific trial settings.

Investigational classification. Some insurers classify certain PET protocols (PSMA PET for prostate cancer, FDG PET for certain rare indications) as experimental, even when they are FDA-approved and consistent with NCCN guidelines.

Medicare Coverage for PET Scans

Medicare's coverage of PET scans is governed by several NCDs, most importantly NCD 220.6:

• FDG PET is covered for most common solid tumors and lymphomas for initial staging, subsequent treatment strategy, and recurrence
• The scan must be ordered by the treating oncologist (not just any physician)
• Documentation must clearly state the specific clinical indication and how the PET will change clinical management
• Beneficiaries must be enrolled in a clinical registry for some indications (Coverage with Evidence Development)

If Medicare denied your PET scan, the appeal pathway includes: redetermination (60 days), QIC reconsideration (180 days), ALJ hearing, Medicare Appeals Council, and Federal Court.

How to Appeal a PET Scan Denial

Step 1: Identify the denial reason precisely. Is it a medical necessity denial? A frequency denial? An indication not covered? An authorization that was never obtained? The appeal strategy differs for each.

Step 2: File an internal appeal with clinical documentation. Your oncologist's letter is your most powerful tool. It should:

• State the specific cancer diagnosis (ICD-10 code), stage, and treatment history
• Explain how PET will change clinical management (not just confirm what is already known)
• Reference NCCN guidelines for your cancer type — NCCN includes specific PET indications for most cancer types
• Address the specific denial criteria the insurer cited
• Note any urgency — is surgical planning on hold pending the PET result?

Step 3: Reference NCCN guidelines. The National Comprehensive Cancer Network (NCCN) publishes evidence-based guidelines for cancer staging and monitoring that include specific PET indications. These guidelines are widely recognized by insurer medical directors and IRO reviewers.

Step 4: Request peer-to-peer review. Your oncologist should request a direct call with the insurer's medical reviewer. Oncologist-to-oncologist conversation (or oncologist to internist) about PET necessity is highly effective, particularly when the insurer's reviewer is not a specialist in your cancer type.

Step 5: File for External Independent Review: Complete Guide" class="auto-link">external review. After internal appeal, file external review through your state insurance department. PET scan denials for established oncologic indications (per NCCN) are frequently overturned at the external review stage.

PSMA PET for Prostate Cancer

PSMA PET (using F-18 piflufolastat or Ga-68 PSMA-11) is FDA-approved and included in NCCN guidelines for prostate cancer staging and restaging. However, many commercial insurers lag behind on coverage, and denials citing "experimental" status are common. Appeal these denials by citing FDA approval, NCCN Category 1 recommendation, and peer-reviewed clinical evidence on PSMA PET's superiority over conventional imaging for prostate cancer.

Fight Back With ClaimBack

ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word.

Fight your denial at ClaimBack →

Related Reading:

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• What Is Prior Authorization?